Form 483 reveals quality control questions and lack of training at Sun Pharma’s plant in India

The FDA has lifted the covers on another drug manufacturing facility in India recently, revealing several concerns around sanitation and improper controls, among other infractions.

Sun Pharma last month received a Form 483 from the agency, with 10 observations for the facility in Halol, India, a small city in the...

Click to view original post